Tempus AI, Inc. (TEM)
Summary
Tempus AI: Winning With Precision Medicine
Tempus AI, Inc. made a timely move to acquire the Personalis cancer monitoring tests to advance AI-driven precision medicine. Recent cancer vaccine developments from Merck and Moderna reinforce the strategic relevance and growth runway for TEM's platform. The company already had strong momentum with higher test ASPs, with the cancer tests a huge bonus.
Tempus AI: The Data Flywheel Has Started Spinning
Tempus AI reported its first GAAP profit, accelerated data business growth, and raised 2026 revenue guidance to $1.595B–$1.605B (+25% Y/Y). Operating leverage from oncology volume and a mix shift to high-margin Data & Apps (72%-75% GM) drove profitability improvement and narrowed cash outflows. FDA approval for xT CDx and higher xF liquid biopsy ASPs is expected to add ~$400M incremental revenue by 2028, with the Personalis acquisition targeting MRD leadership.
Tempus AI's FDA Win Could Unlock Major Reimbursement Growth Ahead
TEM's FDA approval for xT could unlock $85 million in annual revenue from higher pricing, with bigger gains tied to xF.
Tempus AI, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 248 | $14,492.53 | $11,581.6 | -$2,910.93 | -20.09% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 25,271 | $1.46M | $1.32M | -$148,594.48 | -10.15% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 1,830 | $144,320.34 | $101,912.7 | -$42,407.64 | -29.38% |
| RB Robert Bacarella MONETTA FINANCIAL SERVICES Inc. | 20,000 | $1.16M | $1.04M | -$117,200 | -10.12% |
| NA Nizar Araji National Bank Of Canada /FI/ | 5,665 | $365,785.35 | $294,976.55 | -$70,808.8 | -19.36% |
Tempus AI, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SN Subbu Nambi Guggenheim | 270.61 | $14,433.51 | $11,609.24 | -$2,824.27 | -19.57% |
Tempus AI, Inc. (TEM) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Tempus AI, Inc. ever had a stock split?
Tempus AI, Inc. Profile
| Technology Hardware, Storage & Peripherals Industry | Information Technology Sector | Eric Lefkofsky CEO | NASDAQ (NGS) Exchange | 88023B103 CUSIP |
| US Country | 3,800 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Tempus AI, Inc. stands as a vanguard healthcare technology company, specializing in delivering cutting-edge diagnostic solutions. Established in 2015 and based in Chicago, Illinois, its operations encompass a comprehensive range of molecular and anatomic pathology tests. Initially known as Tempus Labs, Inc., the company underwent a rebranding to Tempus AI, Inc. in January 2023. Its offerings are designed to support healthcare providers, pharmaceutical entities, biotechnology firms, researchers, and other third-party organizations. Its mission revolves around the fusion of clinical data and artificial intelligence to forge advancements in healthcare outcomes.
Products and Services
Tempus AI, Inc. has curated a diverse portfolio of products and services, each tailored to address various aspects of healthcare diagnostics and research:
- Next Generation Sequencing Diagnostics: Leveraging comprehensive genomic profiling to aid in the identification of DNA mutations responsible for cancers, guiding personalized treatment plans.
- Polymerase Chain Reaction (PCR) Profiling: Enabling rapid detection and identification of genetic material from a specific organism, useful in diagnosing infectious diseases, among others.
- Molecular Genotyping: Provides essential data for understanding genetic predispositions to diseases, facilitating preventive healthcare strategies.
- Insights: Offers a vast library of de-identified clinical, molecular, and imaging data, coupled with a suite of analytical services. It provides pharmaceutical and biotechnology companies with valuable data analytics capabilities, by employing advanced analytical and cloud-compute technologies.
- Trials: A service designed to match clinical trials with suitable candidates, thus accelerating the drug development process for pharmaceutical companies.
- Next; Algos: This suite presents algorithmic tests specifically in the field of oncology, enhancing the speed and accuracy of cancer diagnosis and treatment planning.
- Hub: A comprehensive platform for healthcare providers, facilitating easy ordering, management, and receipt of tests and patient results through both desktop and mobile interfaces.
- Lens: Exclusively for researchers and scientists, this platform allows the exploration, access, and analysis of Tempus's rich data sets, fostering innovation in medical research.
